Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-25
2005-10-25
Bugaisky, Gabriele (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S326000, C530S300000
Reexamination Certificate
active
06958323
ABSTRACT:
The present invention relates to the use of α-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2is any amino acid, Xaa3is any amino acid, Xaa4is any amino acid, Xaa5is any amino acid; Xaa6is any amino acid, Xaa7is any amino acid, Xaa8is any amino acid, Xaa9is des-Xaa9or any amino acid, Xaa10is des-Xaa10or any amino acid, Xaa11is des-Xaa11or any amino acid and Xaa2is des-Xaa12or any amino acid. Disulfide linkages exist between the first and third cysteines and the second and fourth cysteines. Pro may be replaced with hydroxy-Pro. The C-terminus may contain a hydroxyl or an amide group, preferably an amide group.
REFERENCES:
patent: 4447356 (1984-05-01), Olivera et al.
patent: 5432155 (1995-07-01), Olivera et al.
patent: 5514774 (1996-05-01), Olivera et al.
patent: 5595972 (1997-01-01), Olivera et al.
patent: 5633347 (1997-05-01), Olivera et al.
patent: 5780433 (1998-07-01), McIntosh et al.
patent: 5866682 (1999-02-01), McIntosh et al.
patent: 5922679 (1999-07-01), McIntosh et al.
patent: 5929034 (1999-07-01), McIntosh et al.
patent: WO 95/11256 (1995-04-01), None
patent: WO 98/24462 (1998-06-01), None
Kulak, J.M. et al., “α-Conotoxin MII Blocks Nicotine-Stimulated Dopamine Release in Rat Striatal Synaptosomes,”J. of Neurosci., 1997, 17(14):5263-70.
Tavazoie, S.F. et al., “Differential block of nicotinic synapses on B versus C neurones in sympathetic ganglia of frog by α-conotoxins MII and ImI,”Brit. J. Pharmacol., 1997, 120:995-1000.
Fainzilber, M. et al., “New Mollusc-Specific α-Conotoxins BlockAplysiaNeuronal Acetylcholine Receptors,”Biochemistry, 1994, 33:9523-29.
Cartier G. Edward
Luo Siqin
McIntosh J. Michael
Olivera Baldomero M.
Yoshikami Doju
Bugaisky Gabriele
Cognetix, Inc.
Rothwell Figg Ernst & Manbeck
University of Utah Research Fnd.
LandOfFree
Uses of α-conotoxin peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of α-conotoxin peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of α-conotoxin peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454805